

References

Abizaid A, DeGroot L, Besser G, et al (2004): Dyslipidemia as a strong predictor for mortality and morbidity in diabetic patients with coronary heart disease. *Circulation* 77:1321-1240.

Adler A, Stratton I, Neil H et al (2000) : Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36) prospective observational study. *BMJ*;321:412-9. PMID 10938049.

Adnan M , Kastrati N , Stuelinger M et al., (2004) : Intracoronary Stenting and Angiographic Results of Drug-Eluting Stents for In-stent Restenosis *JACC*, 22:07:11.

Amos A, McCarty D, Zimmet P , et al ., (2010) : The rising global burden of diabetes and its complications. *Diabet* , 1299-14:

Andersen T, Meredith T, Yeung C, et al ., (1995) : The effect of cholesterol lowering and antioxidant therapy on endothelium dependent coronary vasomotion. *N Eng J Med* ;332:488-93.

Ang C, Hillier C, Cameron A, et al (2001) : The effect of type 1 diabetes mellitus on vascular responses to endothelin-1 in pregnant women. *J Clinic Endocrinol Metab*. 86:4939–4942

Aoki J, Serruys P, van Beusekom H, et al ., (2005) : Endothelial progenitor cell capture by stents coated with antibody against CD34: the Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man Registry. *J Am Coll Cardiol.*; 45: 1574–1579

Arampatzis C , Lemos P, Serruys P, et al (2004) : Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "Real World": the Rapamycin Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. *Circulation* 10:190–195

Arani T , Becker E , Xavi U et al.(1975) : Anatomy of the heart & coronary circulation , role of imaging ; *Eur Heart J* ;DOI:10.1093/eurheartj/ehp352.

Armstrong J, Gunn J, Arnold N, et al. (2002) : Angiopeptin-eluting stents: observations in human vessels and pig coronary arteries. *J Invasive Cardiol* ;14:230-8.

Asagami T, Abbasi F, Stuelinger M , et al (2002) : Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. *Metabolism* 51:843–46.

Axel W , Meredith I, Yeung A et al.(2001) : Paclitaxel Inhibits Arterial Smooth Muscle Proliferation and Migration In Vitro and In Vivo *Circulation*. 12:636-645.

Babapulle M & Eisenberg M. (2002) : Coated stents for the prevention of restenosis: part II. *Circulation* .6:677-65

Bakhai A, Stone G, Mahoney E, et al . (2004) : information of the TAXUS-IV Investigators. *JACC* 45:56-98

Banting F, Best C , Collip J, et al (1992) : "Pancreatic extracts in the treatment of diabetes mellitus". *Canadian Med Assoc J* 12: 141–146.

Barsness G, Peterson E, Ohman E, et al (1997) : Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. *Circulation*. ; 96:251–56

Beckman J, Goldfine A, Gordon M, et al (2003) : Oral antioxidant therapy improves endothelial function in type 1 but not type 2 diabetes mellitus. *Am J Physiol Heart Circ* 285:H2392–H2398.

Beckman J & Koppenol W (1996) : Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. *Am J Physiol* 272:C1424–C1437.

Berc B, Gordon J, Alexander R. Et al (1991) : Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. *J Am Coll Cardiol* ;17(suppl B):111B-17.

Berliner J, Navab M, Fogelman A, et al (1995) : Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. *Circulation* ;91:2488-96.

Bhatt D, Fox K, Hacke W, et al (2006) : Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med* ;354(16):1706-1717.

Blindt R, Vogt F, Astafieva I, et al (2006) : A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. *J Am Coll Cardiol.*; 47: 1786–1795

Braun-Dullaes R, Mann M, Dzau V. Et al (1998) : Cell cycle progression new therapeutic target for vascular proliferative disease. *Circulation* 98:82-9.

Broide B & Hanson M (2006) : impact of DES in high risk patients , head to head comparison , *J coll cardiol* 20:89-87

Brophy J, Belisle P, Joseph L et al (2009) : Evidence for use of coronary stents: new era of drug eluting stents analysis of early trials *Ann i. Medscape* ; 138: 777–786.

Browatzki M, Schmidt J, Kubler W, et al (2000) : Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. *Basic Res Cardiol* 95:98–105.

Brownlee M , Fischer U, Gehling U et al (2000) : Negative consequences of glycation. *Metabolism* 49(2 Suppl 1):9–13

Bruce R. Brodie, M, Thomas S et al (2006) : (Strategic Transcatheter Evaluation of New Therapies) LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina . *Cardiol* 76:88-67

Butzal M, Loges S, Schweizer M, et al (2004) : Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. *Exp Cell Res.*; 300: 65–71

Byrne R, Kastrati A, Kufner S, et al (2009) : Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. *Eur Heart J* DOI:10.1093/eurheartj/ehp352.

Calles-Escandon J, Garcia-Rubi E, Mirza S, et al (1999): Type 2 diabetes: one disease, multiple cardiovascular risk factors. *Coronary Artery Disease Cardiol* 10:23-30.

Charanjit R, Miar D , Annan E et al (2007) : Drug-eluting stents: Do they increase heart attack risk? Learn from a Mayo Clinic doctor how to weigh the risks and benefits of stents. *Circ.* 33:867-44

Chen M, John J, Chew D, et al (2006) : Bare metal stent restenosis is not a benign clinical entity. *Am. Heart J.* 151, 1260-1264

Chieffo A, Bonizzoni E, Orlic D et al (2004) : Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. *Circulation.* ; 109: 2732–2736.

Chung I, Gold H, Schwartz M, et al.(2002) : Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. *J Am Coll Cardiol* ;40: 2072-81.

Claessen, B. et. al.(2009) Two Year Clinical, Angiographic and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With de novo Native Coronary Artery Lesions: The SPIRIT II Trial. *Circ Cardiovasc Interventions.* 12:339-347.

Cohen D, Bakhai A, Shi C, et al.(2003) : Cost-effectiveness of sirolimus drug-eluting stents for treatment of complex coronary stenoses: results from the SIRIUS trial. Presented at the 52nd annual scientific sessions of the American College of Cardiology, 30:99-33.

Colombo A, Osler U & Will A .(1995) : Coronary intervention techniques & principles , impaction of balloon dilatation on outcome post procedures ; *Am intervention. J.* 107: 766–744.

Colombo E, Drzewiecki J, Banning A, et al (2003) : TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stent for coronary artery lesions. *Circulation.*; 108: 788–794

Camenzind E,& Nordmann A. (2006) : *Safety of drug-eluting stents: insights from meta analysis*. World Congress of Cardiology, Circ. 115:667-766.

Cosentino F & Luscher T.(1998) : Endothelial dysfunction in diabetes mellitus. *J Cardiovascular Pharmacology* ; 32 (Supply 3) S54-S61.

Costa M & Abizaid A (2000) : Arterial Paclitaxel Distribution and Deposition" - *Circulation Research*. 2000; 86:879-884.

Costa M, Foley D, Serruys P et al (2002) : Restenosis: the problem and how to deal with it. In: Grech ED, Ramsdale DR, eds. *Practical interventional cardiology*. 2nd ed. London: 279-94.

Curfman G , Boon E , Matt W et al (2002) . High lights on Sirolimus-eluting coronary stents. *N Engl J Med*;346:1770-1.

Curfum N, Max E , Morris R et al (2002) :Anonymous. Best of the ACC scientific session. *Rev Cardiovasc Med*;3:85-104.

Cutlip D, Chauhan M, Baim D et al. (2002) : Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. *J Am Coll Cardiol*. 40: 2082–2089.

Cybulsky M & Gimbrone M. (1991) : Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. *Science* ;251:788-91

David E, Kandzari U, Joseph J, et al (2010) : Highlights from the American Heart Association Annual Scientific Sessions 2009: November 11 to 14, *American Heart Journal*;Volume 143. Number 2.

Degertekin M, Serruys P, Foley D, et al.(2002) : Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. *Circulation* 106:1610-13.1

Demer Q , Tallis S , Illwen W et al , (1988) : angiographic imaging parameters , TIMI definition , parameters of calculation .*Eur. intervention J.* 109-149

Detre K, Guo P, Holubkov R, et al.(1999) : Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). *Circulation.*; 99: 633–640.

Dibra A, Kastrati A, Mehilli J, *et al.*(2005) : Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. *N Engl J Med* ;353:663–70.

Donehower R et al (2004) : Food and Drug Administration. TAXUS EXPRESS™ : paclitaxel-eluting coronary stent system. *N Eng J Med* : 435:666-39

Doucet S, SchaliJ M, Vrolix M, et al.(2004) : Stent placement to prevent restenosis after angioplasty in small coronary arteries. *Circulation.* 104:2029–

Duncan C, Chalmers J, Campbell I, *et al.*(1992) : An audit of non-insulin-dependent diabetics attending a district general hospital diabetic clinic: implications for shared care between hospital and general practice. *Health Bulletin* 50:302–8.

Dutcher J, Novik Y, O'Boyle K, et al (2000) : 20th Century advances in drug therapy in oncology: part II. *Clin Pharm* ;40:1079-925.

Dyexler H.et al (1998) : Factors involved in the maintenance of endothelial function. *Am J Cardiol* ; 82 (10A) 35-45.

Eberhart, M; Ogden C, Engelgau M, et al (2007) : "Prevalence of Overweight and Obesity Among Adults with Diagnosed Diabetes --- United States, 1988--1994 and 1999--2002. *Morbidity and Mortality Weekly Report* . US educ. Journal 53 (45): 1066-1068.

El Bekay R, Alvarez M, Monteseirin J, et al (2003) : Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: Involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. *Blood* 102:662–671

Elkeles R, Diamond J, Poulter C, et al (2004) : Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes, *JACC* 134:445-56.

Ellis A, Annan W , king R et al .(1990) : Incidence of Coronary artery diseases , role of imaging modalities in diagnosis and treatment . *Eur Heart J* : 56:10-1093.

Ellis S, Colombo A, Grube E, et al. (2010) : Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. *J Am Coll Cardiol* 49:1043-51.

Eschwège E, Simon D, Balkau B. et al (1997) : The growing burden of diabetes in the world population. *IDF bulletin* 42:14-9.

Esenstein E, Anstrom K, Kong F, et al (2010) : Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. *JAMA*. 297: 159–168.

Fagan T & Deedwania P (1998) : The cardiovascular dysmetabolic syndrome. *Am J Med* . 105 (1A) 775-855.

Farb A , Gurbel N , Dorsam G et al (2002) : The arterial response to PCI follow an injury and repair sequence of events , *Circulation* , 105 : 2974-80).

Farb A, John M, Acampado E, et al. (2009) : Oral everolimus inhibits in-stent neointimal growth. *Circulation* 106:2379-84.

Fernando A, Bann S , Ellis R et al , (2006) :Angiographic definitions , role of quantitative coronary analyses , *Cardiol* . 145:332(80)-14.

Ferreira A, Peter A, Salerno T, *et al* (2003) : . Clinical impact of drug-eluting stents in changing referral practices for coronary surgical revascularization in a tertiary care center. *Ann Thorac Surg* . 75 : 485-9.

Fischman D, Leon M, Baim D *et al.*(1994) : A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. *N Engl J Med* 331:496-501

Fischman D, Leon M, Baim D, *et al* (1994) : Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. *N Engl J Med*.331: 496–501

Foley D, *et al* (2002) :The Multifunctional Effects of Paclitaxel on the Neointimal Cascade: A Close Look at the Role of Microtubules" - Boston Scientific."Arterial Paclitaxel Distribution and Deposition" - *Circulation* 86:879-884.

Francois R, M. Dean T, Laurence T, *et al* (2002) : for C-SIRIUS:The Canadian Multicenter, Randomized, Double-Blind Study of the Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions: *Circ*. 109:554-44 .

Frick M, Elo O, Haapa K, *et al.*, (1997). Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. *N Engl J Med* 317:1237-1245.

Fujii K, Carlier G, Mintz G, *et al* , (2009) : Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. *J Am Coll Cardiol*. 45: 995–998.

Gallo R, Padurean A, Chesebro J, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by rapamycin. *Circulation* 99:2164-70.

Garg Q, Treacy S, Silbaugh, B. et al (2008) : The Massachusetts Data Analysis Center (Mass-DAC) registry American Heart Association . *Eur Inte.j*87:54-44

Genuth S et al (2006). "Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes.". *Endocr Pract* 12: 34-41.

George B , Voorhees W , Roubin G, et al (1993) : Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty . *J Am Coll Cardiol* : 22 : 135-143.

Geraldes P, Sirois M, Bernatchez P, et al. (2002) : Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. *Arterioscler Thromb Vasc Biol* 22:1585-90.

Gibbons G & Dzau V(1994) :. Mechanism of disease: The emerging concept of vascular remodeling. *N Eng J Med* 330: 1431-8.

Gilbert J , Golf S, Myreng Y, et al. (2004) : Stenting in Chronic Coronary Occlusion (SICCO): A randomized controlled trial of adding stent implantation after successful angioplasty. *J Am Coll Cardiol* 28:1444-1451. Abstract.

Gilbert J, Raboud J, Zinman B et al (2004) : Meta analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. *Diabetes Care* 27:990–994

Gilewski T, Dang C, Sarborne A, et al (2002) : Principles of chemotherapy: cytokines. In *Cancer Medicine*, 5th ed. Philadelphia 667;11-38.

Goldstein B et al (2002) : Insulin resistance as the core defect in type 2 diabetes mellitus. *Am J Cardiol* 90:3G–10G, 2002

Glagov S, Weisenberg E, Zarins C, et al (1997) : Compensatory enlargement of human atherosclerotic coronary arteries. *N Engl J Med*. 16:1371–1375

Gossain V et al (2000) : The rising global burden of diabetes e. *Diabetes*, International Diabetes Federation *Am Cardiol* P. 17: 19-70.

Greenberg D, Bakhai A, Cohen J. et al (2004) : Can we afford to eliminate restenosis? Can we afford not to? *J Am Col Cardiol* **43** (4): 513-18.

Griese D, Ehsan A, Melo L, et al (2003) : Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. *Circulation*. 108: 2710–2715

Grube E , Shinjo S, Annan W et al (2004). "Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer". *Circulation* 109: 2168—2171.

Gruentzig A et al (1978) : Transluminal dilatation of coronary artery stenosis. *Lancet* 1: 263

Gruentzig AR, Senning A, Siegenthaler WE. : Nonoperative dilatation of coronary-artery stenosis. *N Engl J Med* 1979;301:61-8.

Gurbel P, Callahan K, Malinin A, et al (2002) : . Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. *J Invasive Cardiol*. 14: 584–589.

Gurbel P *et al.* (2005) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. *J Am Coll Cardiol* 46: 1827–1832

Haffner S *et al* (1999). Diabetes, Hyperlipidemia, and Coronary Artery Disease. *Am J Cardiol* 83:17F-21F.

Harris M *et al* (1995) : the National Diabetes Data Group of the National Institutes of Health, and the National Institute of Diabetes and Digestive and Kidney Diseases,. *Diabetes in America*, 2nd ed.

Himsworth A & Campelle E (1996). "Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types". *Lancet* i: 127–130.

Hooks M. *Et al* (1994) : Tacrolimus, a new immunosuppressant: a review of the literature. *Ann Pharmacotherapy* 28(4):501-11.

Iakovou I, Schmidt T, Bonizzoni E, *et al.* (2005) : Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. *JAMA* 293:2126-2130.

Inoguchi T, Li P, Umeda F, *et al* (2000) : High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. *Diabetes* 49:1939–1945.

Ishii H, Jirousek M, Koya D, *et al* (1996) : Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. *Science* 272:728–731.

Ito A, Tsao P, Adimoolam S, *et al*(1999) : Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. *Circulation* 99:3092–3095.

Jack E, Moses W , Norwood A et al (2007) : Study of ICES and Sunnybrook Health Sciences Centre, University of Toronto , McMaster University, and Trillium Health Centre, Mississauga,– Canadian Cardiology J. 10 : 55-44 page : 22.

James S. et al (2007) : Long term mortality after drug-eluting stents in Sweden – one additional year of follow-up. Clinical trial update I #1021. Presented at: The European Society of Cardiology Congress . Eur. Heart . j . 103:55-55.

Jeff M & Scott Y (2010) : the 56th Annual Scientific Session of the American College of Cardiology (ACC) conference in New Orleans. . JACC. 104:89-88 .

Jens M , Flensted A , Lassen D, et al (2010) : Multicenter, randomized study of Skejby Hospital in Aarhus, Denmark , SORT OUT III , JACC ; 1188-67.

Jimenez A, Quevedo P, Angiolillo J, et al (2005) : Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation : 112(14) : 2175-83 .

Jong R , Hainze A , Queen S et al ., (2001) : Angiographic outcome post coronary intervention ; definition , early & late complications , JACC . 4455(70)-34 .

Kaburagi Y, Yamauchi T, Yamamoto-Honda R, et al(1999) : The mechanism of insulin-induced signal transduction mediated by the insulin receptor substrate family. Endocr J 46(Suppl):S25–S34, .

Kapur A, Malik I S ,Bagger J P, et al (2005) :. The Coronary Artery Revascularization in Diabetes(CARDia)trial: background,aims and design. *Am Heart J* ;149:13-9

Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease meta-analysis of randomized trials. JAMA ;294:819-825

Kaiser C et al. "Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomized Basel Stent Kosten Effectiveness Trial (BASKET)" *Lancet* 366:921-929

Kereiakes D, Moses J, Leon M, et al.(2003) ; Durable clinical benefit following CYPHER coronary stent deployment: SIRIUS study 2-year results . *Circulation* 108(suppl IV):IV-532.

Kereiakes D et al (2003) : Inflammation as a therapeutic target: a unique role for abciximab.*Am Heart J* , 146:S1-4.

Kevin K et al (2004) : Lecture Notes, Brown University :new era of DES & the future of coronary stenting , 12:65-5

Kimmel S , Berlin A , Laskey K (1995) : The relationship between coronary angioplasty procedure volume and major complications . *JAMA* : 274:1137-42.

Knowler W, Barrett-Connor E, Fowler S, et al (2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.". *N Engl J Med* 346 (6): 393-403.

Komatsu R, Ueda M, Naruko T, et al (1998) : Neointimal tissue response at sites of coronary stenting in humans. Macroscopic, histological and immunohistochemical analysis *Circulation* 98:224-233

Koya D & King G : Protein kinase C (1998) : activation and the development of diabetic complications. *Diabetes* 47:859–86.

Krensky A, Alan M.; Flavio V, et al : (2006). "Immunosuppressants, Tolerogens, and Immunostimulants", in Laurence L. Brunton, John S. Lazo, & Keith L. Parker Goodman & Gilman 11th ed., New York: McGraw-Hill, 1413.

Kuchulakanti P, Chu W, Torguson R, et al (2006) : Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. *Circulation.* ; 113: 1108–1113.

Kuntz R, Safian R, Carrozza J, Fishman et al (1992): The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. *Circ* 86:1827-35

Laasko M, Lehto S, Penttilä I et al (1993). Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. *Circulation* 88:1421-1430.

Laing S, Swerdlow A, Slater S, et al.(1999) : The British Diabetic Association cohort study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. *Diabet Med* 16:466–71.

Lamarche B, Tchernof A, Mauriege P, et al : Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. *JAMA* 279:1955-1961.

Lansky A, Ng G, Mutlu H, et al (2009) : Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system:: clinical and angiographic results from the SPIRIT III randomized trial. *US Cardiovasc Interv.* [11:90-99]

Lin KY, Ito A, Asagami T, et al: Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. *Circulation* 106:987–992, 2002.

Liu X, Huang Y, Hanet C, et al.(2003) : Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. *Catheter Cardiovasc Interv* 60:172-8.

Luis G., Mark M, Gousief F. Et al (2007) ; *Sirolimus- vs Paclitaxel-Eluting Stents in Real-World Lesions SORT OUT II trial* :*circulation* 126:55-55

Lüscher F, Steffel J, Eberli R, et al (2007) : .Cardiovascular Center, University of Zurich, Rämistrasse 100, 8091 Zürich, Switzerland., *circulation* 123:44-565

Luscher T, Steffel J, Eberli F, et al .(2007) :Drug-eluting stent and angiographic outcome , complications of coronary thrombosis: biological mechanisms and clinical implications. *Circulation* 115(8):1051-1058.

Mahgoub MA & Abd-Elfattah AS(1998) : Diabetes mellitus and cardiac function. *Mol Cell Biochem* 180:59–64

Manolio A, Baughman K, Rodeheffer R, et al(1999) : Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). *Am J Cardiol* 69:1458

Marso S, Lincoff A, Ellis S, et al.(1999) : Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy. *Circulation*. 100: 2477–2484.

Martinez-Elbal L, Ruiz-Nodar JM, Zueco J, et al. (2002) : Direct coronary stenting versus stenting with balloon pre-dilation: immediate and follow-up results of a multicentre, prospective, randomized study. The DISCO trial. Direct stenting of coronary arteries. *Eur Heart J* 23:633-40.

Marx S, Jayaraman T, Go L, et al.(1995) : Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. *Circ* 76:412-17.

Marx S & Marks A. (2001) : Bench to bedside: the development of rapamycin and its application of stent restenosis. *Circulation* 104:852-5.

Mauri L, Hsieh WH, Massaro J, et al (2007) : Stent thrombosis in randomized clinical trials of drug-eluting stents. *N Engl J Med* ;356:1020-9.

Mehilli J,Dibra A,Kastrati A, et al (2006) : randomized trial of PES & SES in small coronary vessels . *Eur Heart J* 27:260-6

Mendenhal Q, Ann Y & Culip A (1986) : Statistical analysis , definitions , comparisons & programming ; role of chi square . *Lanc. Education j*. 445-1009.

McAuley DF, McGurk C, Nugent AG, et al (2000) : Vasoconstriction to endothelin-1 is blunted in non-insulin-dependent diabetes: A dose-response study. *J Cardiovasc Pharmacol* 36:203–208.

McFadden EP, Stabile E, Regar E, et al(2004) : Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy *Lancet*;364:1519-1521.

Meyer B & Meier B.(2009) Percutaneous transluminal coronary angioplasty of single or multivessel disease and chronic total occlusions. In: Grech ED, Ramsdale DR, eds. *Practical interventional cardiology*. 2nd ed. London: 35-54.

Michael M, Lisette O.Jensen, A, et al (2009) ;. Stent thrombosis after implantation of drug-eluting or bare metal coronary stents in Western Denmark. *JACC* 123:556-898.

Michel A & Thomas E (2006). "Treatment of Myocardial Ischemia", in Laurence L. Brunton, John S. Lazo, & Keith L. Parker Goodman & Gilman 11th ed., New York: 84:99-99

Miettenen H, Lehto S, Salomaa V, et al (1998). Impact of diabetes on mortality after first myocardial infarction. *Diabetes Care* 21:69-7

Montagnani M, Golovchenko I, Kim I, et al(2002) : Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. *J Biol Chem* 277:1794–1799.

Morice M, Serruys W, Sousa E et al :(2002)A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* ;346(23):1773-1780.

Morice M , Colompo A, Miere B, et al : SES vs PES in de novo lesions . the REALITY results , *JAMA* 295-904, 2006

Morigi M, Angioletti S, Imberti B, et al (1998) : Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF- κ B-dependent fashion. *J Clin Invest* 101:1905–1915.

Morris W , Ito M , Wallis A (1997) : BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). *Circulation*. 96: 1761–1769.

Morice M, Serruys P, Sousa J, et al (2002) : A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med*. 346: 1773–1780.

Moses J, Leon M, Popma J et al (2003) : Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med*:1315-23.

Narins C, Holmes D , Topol E et al (1998) : A call for provisional stenting: the balloon is back. *Circulation* 97:1298–1305

New G, Moses J, Roubin S, et al.(2002) : Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. *Catheter Cardiovasc Inter* 57:266-71.

Nebeker J, Virmani R, Bennett C, et al (2009) : Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. *J Am Coll Cardiol*. 47: 175–181.

Niels Grabow, David P. Martin, Klaus-Peter Schmitz, et al (2009) : *Journal of Chemical Technology & Biotechnology*:n/a-n/a (2009)

Niles N, McGrath P, Malenka D, et al.(2008) Northern New England Cardiovascular Disease Study Group: survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. *J Am Coll Cardiol*. 37: 1008–1015.

Nishikawa T, Edelstein D, Du XL, et al(2000) : Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature* 404:787–790

Oberhoff M, Herdeg C, Baumbach A, et al (2002) : Stent-based antirestenotic coatings. *Cath Cardio Interv* 55:404-8.

Olefsky J, Colompo A, Miere B ,et al (1998) : Pathogenesis of insulin resistance and hyperglycemia in non-insulin dependent diabetes mellitus (type 2). *In Endocrinology 2nd Edition (eds).*; p1369-88.

Ong A, Hoyer A, Aoki J, van Mieghem C, et al (2005) : . Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. *J Am Coll Cardiol.* 45: 947–953.

Ong A, McFadden E, Regar E, et al (2005) : Late angiographic stent thrombosis (LAST) events with drug-eluting stents *J Am Coll Cardiol* ;45:2088-2092.

Parisi A , Folland E , Hartigan P (1992) : A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease . *N Eng J Med* : 326 : 10-6 .

Park L, Raman KG, Lee KJ, et al (1998) : Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. *Nat Med* 4:1025–1031

Park D, Park S, Park K,et al (2006) : . Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. *Am J Cardiol.* 98: 352–356.

Parry T, Brosius R, Thyagarajan R, et al (2005) : Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. *Eur J Pharmacol.* ; 524: 19–29

- Peter F & Shimohama U (2007) : Stanford University , Medical Center for Cardiovascular Technology (Drug-eluting stent controversy explored in the American Heart Hospital Journal) *Am Cardiol* 108:77-998
- Pieper G & Riaz H (1997) : Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: Prevention by calphostin C. *J Cardiovasc Pharmacol* 30:528–532.
- Poon M, Marx O, Gallo R, et al.(1996) : Rapamycin inhibits vascular smooth muscle cell migration. *J Clin Invest* 98:2277-83.
- Praet S, Jonkers A, Schep G, et al : (2008) : Nutrition and Toxicology Research Institute Maastricht, Maastricht University, DM & coronary artery disease . *Eur . c. j.* 4:55-77
- Prescott M & Virmani R (2004) : Food and Drug Administration. CYPHER™ sirolimus-eluting coronary stent on RAPTOR® over-the-wire delivery system or RAPTORRAIL® rapid exchange delivery system. *Circ.* 104:88-99
- Quyyumi A. et al (1998) : Endothelial function in health and disease. *Am J Med*; 105 (1A) S32-S39.
- Reaven G. et al (1984) : Insulin secretion and insulin action in non-insulin dependent diabetes mellitus: Which defect is primary. *Diab Care* 7(Suppl 1) 17-24.
- Robert D *et al.* (2000): Cordis V. Boston Scientific Preliminary safety trials on Sirolimus polymer eluting stents *Circ.* 103:03-027
- Robert O. Bonow M., Donald E. et al (2007) : *DES versus BMS outcome in diabetics : Circulation.* (Journal Report 134:556-766)
- Rodrigues B, Cam M, McNeill J (1998) : Metabolic disturbances in diabetic cardiomyopathy. *Mol Cell Biochem* 180:53–57
- Rogers et al (2000) : Paclitaxel release from inert polymer material-coated stents curtails coronary in-stent restenosis in pigs" -. - *Circulation.* 102 (18 Supplement):II566-II567.
- Roubin GS & Douglas JS (1988) : Influence of balloon size on initial success , acute complications and restenosis after angiography . *Circulation* 78 : 557 – 565

Rosen P, Nawroth P, King G, et al (2001) : The role of oxidative stress in the onset and progression of diabetes and its complications: A summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association, and the German Diabetes Society. *Diabetes Metab Res Rev* 17:189–212.

Rowinsky K, Donehower R. , Donan W et al (1995) : Paclitaxel in prevention of Cell mitosis : *N Eng J Med* 32:1001-14.

Rubino F, Gagner M. , Willim E et al (2002) : Potential of surgery for curing type 2 diabetes mellitus. *Ann Surg*;236:554-9.

Rubler S, Dlugash J, Yuceoglu Y, et al (1972) : New type of cardiomyopathy associated with diabetic glomerulosclerosis. *Am J Cardiol* 30:595–602

Schachinger V, Britten B& Zeiher AM et al (2004) : Diabetes mellitus and coronary artery disease-a high risk combination *Eur Heart J*. Jan;25(2):107-12.

Schampaert E , Cohen EA , Schluter M ,(2004) et al : The Canadian study of the sirolimus eluting stent in the treatment of patients with long de novo lesions in small arteries (C-SIRIUS) , *J Am Coll Cardiol* :43:1110-5

Schmidt A, Yan S, Wautier J,et al (1999) : A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. *Circ Res* 84:489–497

Schofer J, Schluter M, Gershlick A, et al (2003) :. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). *Lancet* 362:1093-9.

Schofer J, Schluter M, Rau T, et al (2004) : coronary stenting in diabetic patients: A controlled study. *J Am Coll Cardiol* –35(6):1554-9.

- Schinozaki K, Kashiwagi A, Nishio Y, et al (1999) : Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/ O_2^- imbalance in insulin-resistant rat aorta. *Diabetes* 48:2437–2445
- Schuler W, Sedrani R, Cottens S, et al. (1997) : a new rapamycin derivative: pharmacological properties in vitro and in vivo. *Transplantation Eur . Card. J.* 64:36-42.
- Schuurman H, Cottens S, Fuchs S, et al. (1997) : a new rapamycin derivative: synergism with cyclosporine. *Transplantation Lancet* :64:32-5.
- Schwartz R. Chronos N. Virmani R. Et al (2004). Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. *J Am Coll Cardiol* 44: 1373-1385
- Serruys P, DeJaegere P, Kiemeneij F et al. (1994) : A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. *N Engl J Med* ;331:489-95.
- Serruys P, Patrick W.; Michael J. et al (2006). "Coronary-Artery Stents". *New England Journal of Medicine* 354 (5): 483–495.
- Serruys P, de Jaegere P, Kiemeneij F, et al(2006) : A comparison of bare metal stent implantation vs DES in patients with coronary artery disease. *N Engl J Med* 331: 489–495
- Serruys P & Daemen J: (2007) : Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis. A nuisance in both bare metal and drug-eluting stents. *Circulation* 115(11), 1433-1439
- Sharon N et al (2008) : safety differences between the BMS & DES stents , *Am Cardiol* 441:33-76.
- Sievers T, Rossi S, Ghobrial R, et al.(1997) : Mycophenolate. Pharmacotherapy in coronary artery diseases . *Lancet* 17(6):1178-97

Sigwart U, Kaufmann U, Mirkovitch V, et al (1987) : Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. *N Engl J Med* 316:701-6.

Silva J, Ramee R, White J, et al (1999) : Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. *Am Heart J*. 138: 446–455.

Smith S , Dove J, Jacobs A, , et al.(2001) : ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). *J Am Coll Cardiol* ;37: 2215-39.

Sobel B, Frye R , Detre K.et al (2003) : dilemmas in the management of diabetes and cardiovascular disease: rational for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2 D) trial.*Circulation* 107:636-42

Solang L, Malmberg K, Ryden L et al (1999) : Diabetes mellitus and congestive heart failure. *Eur Heart J* 20:789–795.

Sollott S, Cheng L, Pauly R, et al.(1995) : Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. *J Clin Invest* 95:1869-76.

Sousa , , Serruys P, Abizaid A, et al (2001) : Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries. *Circulation*. 103: 192-195

Sousa JE, Costa MA, Abizaid A, et al.(2003): Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. *Circulation* 107:24-7.

Sousa J, Costa M, Abizaid A, et al. (2004) : Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. *Circulation* 4:207-11.1

Sousa JE, Serruys PW, Costa MA. et al (2003) : New frontiers in cardiology: Drug-eluting stents: Part I. *Circ* ;107:2274-9.

Steffel J, Latini RA, Akhmedov A, et al (2005) : Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. *Circulation*. 112:6555-65.

Steinberg HO & Baron AD (2002) : Vascular function, insulin resistance, and fatty acids. *Diabetologia* 45:623–634.

Stein B, Weintraub W, Gebhart S, et al. (1995) : Coronary heart disease/myocardial infarction: Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. *Circulation*. 91: 979–989

Stitt A, Bucala R, Vlassara H et al (1997) : Atherogenesis and advanced glycation: Promotion, progression, and prevention. *Ann N Y* 811:115–127

Stone G, Moses W, Ellis S, et al. (2007) : Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. *N Engl J Med* 356:998-1008.

Stettler C, Wandel S, Allemann S, et al.(2007) : Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. *Lancet* .370:937-48.

Suzuki T, Kopia G, Hayashi S, et al. (2001) : Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. *Circulation* :1188-93.

Tanabe K, Serruys P, Grube E, et al.(2003) : TAXUS III: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. *Circulation* 107:559-64.

- Tesfamariam B & Cohen A (1995) : Enhanced adrenergic neurotransmission in diabetic rabbit carotid artery. *Cardiovasc Res* 29:549–554
- Topol E & Serruys P. (1998) : Frontiers in interventional cardiology. *Circulation* 98: 1802-20.
- Tré R. Welch, Robert C. Eberhart, et al (2009) : Journal of Biomedical Materials Research Part B: Applied Biomaterials 90B(1):302-311
- Tsuji, T, Tamai, K. Igaki, E. et al (2003). "Biodegradable stents as a platform to drug loading." . *International Journal of Cardiovascular Interventions* 5 (1): 13–6. PMID 12623560.
- Uemura S, Matsushita H, Li W, et al (2001) : Diabetes mellitus enhances vascular matrix metalloproteinase activity: Role of oxidative stress. *Circ Res* 88:1291–1298.
- Urao N, Okigaki M, Yamada H, et al (2006) : Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. *Circ Res.* 98: 1405–1413
- Vasquez E. et al (2000) : Sirolimus a new agent for prevention of renal allograft rejection. *Am J Health-Syst Pharm* 58:437-8
- Velianou J, Mathew V, Wilson S, et al. (2000) : Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation. *Am J Cardiol.* 86: 1063–1068.
- Vibhuti N Singh M Ammn A et at (2004) : "Coronary Artery Atherosclerosis" cost – effectiveness of era of DES . *JACC* . 78/900.1
- Vicent D, Ilany J, Kondo T, et al (2003) : The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. *J Clin Invest* 111:1373–1380.
- Vinik A, Fishwick D, Pittenger G et al (2004) : Advances in diabetes for the millennium: toward a cure for diabetes. *MedGenMed*;6:12.

Virmani A et al (2006) : Problems Resurface with Drug-Eluting Stents
World Congress of Cardiology / European Society of Cardiology annual
meeting in Barcelona , JACC 134:756-86

Vogt F;Andreas S, Gösta R, et al (2004). "Long-term assessment of a
novel biodegradable paclitaxel-eluting coronary polylactide stent".
European Heart Journal 25: 1330–1340.

Wagenknecht L, D'Agostino B Haffner SM, et al (1998). Impaired
glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin
Resistance Atherosclerosis Study. *Diabetes Care* 21:1812-1818.

Wautier J& Guillausseau P (1998) : Diabetes, advanced glycation end
products, and vascular disease. *Vasc Med* 3:131–137.

Weiss J & Sumpio B (2006) : "Review of prevalence and outcome of
vascular disease in patients with diabetes mellitus.". *Eur J Vasc Endovasc
Surg* 31 (2): 143-50.

Wenaweser P, Dorffler-Melly J, Imboden K, et al (2005) : Stent
thrombosis is associated with an impaired response to antiplatelet
therapy. *J Am Coll Cardiol.* 45: 1748–1752.

Wijns W, Schofer J, Breithardt G, et al (2003) : The European
multicentre, randomized, double-blind study of the sirolimus-eluting stent
in the treatment of patients with de novo coronary artery lesions (E-
SIRIUS): 1-year clinical outcomes. *Circ.* 123:45-43

Williams B, Goldfine B, Timimi K, et al (1998) : Acute hyperglycemia
attenuates endothelium-dependent vasodilation in humans in vivo.
Circulation 97:1695–1701.

Windecker S, Remondino A, Eberli R, et al (2005) : Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization N Engl J 353:653-662.[

Witztum L et al (1997) : Role of modified lipoproteins in diabetic macroangiopathy. Diabetes 46(Suppl 2):S112–S114

Ziegler T, Brunner H, Ruiz J et al (1995) : The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. *Ann Intern Med* 1995;122:561-8

Zou M, Yesilkaya A, Ullrich V et al (1999) : Peroxynitrite inactivates prostacyclin synthase by heme-thiolate-catalyzed tyrosine nitration. *Drug Metab Rev* 31:343–349.